Stock listing
OTC:BBIXF Bonus Biogroup Ltd. Stock
US listing (OTC) of Bonus Biogroup Ltd. · home listing TASE:BONS
Follow Bonus Biogroup Ltd. into a list and get an email when it puts out news.
Share price · OTC:BBIXF
$0.04 USD 0.00 (0.0%)
Close on Nov 11, 2026
- Day range
- $0.04 – $0.04 USDNov 11, 2026
- Volume
- 3,000 sharesNov 11, 2026
- 52-week range
- $0.03 – $0.15 USDLowest and highest trades, Nov 12, 2025 – Nov 11, 2026
- Traded on an average day
- $10 USDMedian day 0 shares · 58 days with no trades · last 3 months, Aug 11, 2026 – Nov 11, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:BONS · Home | 15.00 ILA (agorot) | -0.50 (-3.2%) | 1,440,573 | 15.70 | 15.90 | 15.00 | 15.50 | Close on Nov 19, 2026 |
| OTC:BBIXF | $0.04 USD | 0.00 (0.0%) | 3,000 | $0.04 | $0.04 | $0.04 | $0.04 | Close on Nov 11, 2026 |
Daily closes
Last 3 months, Aug 11, 2026 – Nov 11, 2026 · OTC:BBIXF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 3,000 | |
| $0.04 | -0.01 | -20.0% | $0.04 | $0.04 | $0.04 | 500 | |
| $0.05 | 0.00 | 0.0% | $0.05 | $0.05 | $0.05 | 0 | |
| $0.05 | 0.00 | 0.0% | $0.05 | $0.05 | $0.05 | 0 | |
| $0.05 | +0.01 | +25.0% | $0.05 | $0.05 | $0.05 | 1,000 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | +0.01 | +33.3% | $0.04 | $0.04 | $0.04 | 1,000 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | -0.01 | -25.0% | $0.03 | $0.03 | $0.03 | 9,200 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | +0.01 | +33.3% | $0.04 | $0.04 | $0.04 | 1,000 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | -0.01 | -25.0% | $0.03 | $0.03 | $0.03 | 400 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | 0.00 | 0.0% | $0.04 | $0.04 | $0.04 | 0 | |
| $0.04 | -0.04 | -50.0% | $0.04 | $0.04 | $0.04 | 2,000 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 |
- Ticker
- OTC:BBIXF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest deck · Mar 12, 2026
IPO Roadshow (March 2026)
IPO roadshow · 43 slides
Latest news
Bonus Biogroup Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in all · newest Jul 14, 2025 · oldest 2025
- Decks
- 6 decks · latest Mar 12, 2026
Where Bonus Biogroup Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:BONS · Home listing | TASE | Israel | ILA |
| NASDAQ:BONS | NASDAQ | United States | USD |
| OTC:BBIXF · This page | OTC | United States | USD |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- 182.9M ILS
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.17M | US$13.16M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Aldeyra Therapeutics, Inc. · NASDAQ:ALDX | US$50.70M | US$9.72M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 0.66 |
| Clene Inc. · NASDAQ:CLNN | US$50.69M | US$58.31M | n/a | 245× | n/a | n/a | n/a | n/a | 1.48 |
| Median of the others | US$52.10M | US$11.44M | 33.0× | 3.8× | 0.9× | −393.3% | 0.0× | 0.66 |
Team and board
Officers
| Officer | Role |
|---|---|
| Shai Meretzki | Founder & CEO |
| Atara Novak | VP Research & Development |
| Corinne Chemouny | VP Quality Assurance |
| Meital Enbar | VP of Finance |
| Tomer Bronshtein | VP of Innovation & Corporate Development |
| Vered Kivity | VP Regulatory & Clinical Affairs |
| Dror Ben David | Chief Operations Officer |
| Yossi Rauch | Executive Chairman of the Board |
Board
| Director | Role |
|---|---|
| Yossi Rauch | Executive Chairman of the Board |
| Alon Ariel | Director |
| Benjamin Shafir | Director |
| Gil Shapira | Director |
| Margalit Assayag | Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPO Roadshow (March 2026) | IPO roadshow | 43 slides | Mar 12, 2026 |
| Investor Presentation (2025) | Investor deck | 42 slides | 2025 |
| Investor Presentation (April 2022) | Investor deck | 55 slides | April 2022 |
| Investor Presentation (March 2018) | Investor deck | 35 slides | March 2018 |
| Investor Presentation (August 2016) | Investor deck | 27 slides | August 2016 |
| Investor Presentation (July 2016) | Investor deck | 19 slides | July 2016 |
Financials
Annual, in ILS
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 2.76M | 2.79M | 2.76M | 3.37M | 4.10M | 1.61M | 1.34M | 1.14M | ||
| Gross profit | -2.76M | -2.79M | -2.76M | -3.37M | -4.10M | -1.61M | -1.34M | -1.14M | ||
| Research and development | 11.2M | 17.6M | 18.6M | 21.3M | 19.5M | 10.4M | 11.1M | 10.8M | 10.9M | 8.56M |
| Selling, general and administrative | 2.49M | 10.2M | 11.2M | 5.46M | 31.3M | 2.80M | 2.39M | 7.63M | 9.24M | 9.06M |
| Operating income | -22.6M | -27.8M | -28.3M | -37.0M | -64.7M | -19.4M | -20.9M | -18.4M | -20.1M | -16.0M |
| Depreciation and amortization | 2.76M | 2.79M | 2.76M | 2.66M | 1.48M | 1.07M | 1.08M | 197.0K | 163.0K | 410.0K |
| EBITDA | -19.9M | -25.0M | -25.6M | -34.4M | -63.3M | -18.4M | -19.8M | -18.3M | -20.0M | -15.6M |
| Interest expense | 703.0K | 797.0K | 879.0K | 891.0K | 569.0K | 473.0K | 460.0K | 364.0K | 67.0K | 83.0K |
| Income before tax | -24.5M | -27.8M | -28.5M | -38.7M | -90.1M | -22.0M | -22.2M | -18.7M | -20.2M | -16.0M |
| Income tax | -15.0K | -195.0K | 79.0K | 0 | 119.0K | |||||
| Net income | -24.5M | -27.8M | -28.5M | -38.7M | -90.1M | -22.0M | -22.2M | -18.7M | -20.2M | -16.0M |
| Earnings per share, basic | -0.04 | -0.02 | -0.02 | -0.06 | -0.16 | -0.02 | -0.03 | -0.02 | -0.02 | -0.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 228.0K | 6.86M | 12.9M | 53.6M | 79.5M | 16.1M | 105.0K | 8.64M | 2.73M | 1.40M |
| Receivables | 624.0K | 92.0K | 250.0K | 505.0K | 1.16M | 410.0K | 102.0K | 424.0K | 1.88M | 642.0K |
| Current assets | 1.75M | 7.19M | 26.4M | 54.4M | 81.0M | 16.7M | 308.0K | 9.09M | 4.65M | 2.08M |
| Property, plant and equipment | 19.8M | 15.0M | 5.73M | 6.58M | 973.0K | 829.0K | 717.0K | |||
| Goodwill | 39.0K | |||||||||
| Total assets | 15.4M | 23.4M | 44.9M | 74.6M | 104.3M | 51.4M | 6.99M | 10.2M | 5.58M | 2.90M |
| Accounts payable | 1.84M | 1.01M | 1.41M | 1.95M | 3.99M | 1.56M | 1.48M | 1.22M | 1.05M | 1.35M |
| Current liabilities | 14.0M | 7.92M | 5.91M | 7.62M | 8.77M | 16.4M | 15.5M | 12.4M | 12.0M | 10.3M |
| Total debt | 8.90M | 10.2M | 11.2M | 12.0M | 12.3M | 5.15M | 5.88M | |||
| Total liabilities | 21.1M | 16.4M | 15.6M | 18.2M | 19.9M | 20.8M | 20.7M | 13.3M | 12.0M | 10.3M |
| Shareholders' equity | -5.66M | 6.96M | 29.3M | 56.4M | 84.4M | 30.7M | -13.7M | -3.18M | -6.38M | -7.36M |
| Shares outstanding | 669.7M | 1.17B | 1.17B | 621.1M | 579.1M | 1.03B | 841.5M | 811.7M | 809.6M | 233.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14.9M | -21.4M | -26.4M | -28.8M | -39.8M | -15.7M | -13.1M | -13.4M | -11.8M | -9.63M |
| Capital spending | -12.0K | -342.0K | -824.0K | -6.39M | -5.81M | -254.0K | -187.0K | -341.0K | -269.0K | -191.0K |
| Free cash flow | -14.9M | -21.7M | -27.2M | -35.2M | -45.6M | -16.0M | -13.3M | -13.8M | -12.1M | -9.82M |
| Cash from investing | -12.0K | 12.7M | -14.3M | -6.29M | -6.18M | -254.0K | -187.0K | -341.0K | -269.0K | -180.0K |
| Cash from financing | 8.41M | 2.55M | -1.16M | 2.13M | 113.4M | 31.9M | 4.92M | 19.6M | 13.4M | 6.79M |
| Share buybacks | 13.4M | 6.79M | ||||||||
| Change in cash | -6.63M | -6.08M | -40.7M | -25.9M | 63.5M | 16.0M | -8.54M | 5.92M | 1.32M | -3.01M |
Cap table
Built by 6ix from Bonus Biogroup Ltd.’s releases
- Common shares
- 1,167,925,311
- Fully diluted
- 1,167,925,311
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,167,925,311 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,167,925,311 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alon Ariel | Director · Since at least Nov 6, 2026 |
| Atara Novak | VP Research & Development · Since at least Nov 4, 2026 |
| Benjamin Shafir | Director · Since at least Nov 6, 2026 |
| Corinne Chemouny | VP Quality Assurance · Since at least Nov 4, 2026 |
| Dror Ben David | Chief Operations Officer · Since at least Nov 4, 2026 |
| Gil Shapira | Director · Since at least Nov 4, 2026 |
| Margalit Assayag | Director · Since at least Nov 6, 2026 |
| Meital Enbar | VP of Finance · Since at least Nov 4, 2026 |
| Shai Meretzki | Founder & CEO · Since at least Jul 14, 2025 |
| Tomer Bronshtein | VP of Innovation & Corporate Development · Since at least Nov 4, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Vered Kivity | VP Regulatory & Clinical Affairs · Since at least Nov 4, 2026 |
| Yossi Rauch | Executive Chairman of the Board · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Bonus Biogroup Ltd.